Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.740
-0.190 (-4.83%)
Mar 6, 2026, 11:10 AM EST - Market open
Prime Medicine Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 4.63 | 2.98 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 55.28% | - | - | - | - | Upgrade
|
| Cost of Revenue | 160.64 | 155.29 | 147.91 | 86.73 | 70.55 | Upgrade
|
| Gross Profit | -156 | -152.31 | -147.91 | -86.73 | -70.55 | Upgrade
|
| Selling, General & Admin | 52.35 | 50.16 | 43.39 | 29.82 | 13.92 | Upgrade
|
| Operating Expenses | 52.35 | 50.16 | 43.39 | 29.82 | 13.92 | Upgrade
|
| Operating Income | -208.35 | -202.47 | -191.29 | -116.54 | -84.47 | Upgrade
|
| Interest & Investment Income | 4.15 | 3.52 | 2.81 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.15 | 0.04 | 0.27 | 1.9 | -80.99 | Upgrade
|
| EBT Excluding Unusual Items | -204.05 | -198.9 | -188.21 | -114.64 | -165.46 | Upgrade
|
| Gain (Loss) on Sale of Investments | 2.91 | 3.02 | 3.3 | -8.13 | -0.39 | Upgrade
|
| Other Unusual Items | - | - | -13.5 | - | - | Upgrade
|
| Pretax Income | -201.14 | -195.88 | -198.41 | -122.77 | -165.85 | Upgrade
|
| Income Tax Expense | - | - | -0.28 | -0.95 | -0.49 | Upgrade
|
| Net Income | -201.14 | -195.88 | -198.13 | -121.82 | -165.37 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 20.19 | 18.75 | Upgrade
|
| Net Income to Common | -201.14 | -195.88 | -198.13 | -142.01 | -184.12 | Upgrade
|
| Shares Outstanding (Basic) | 149 | 119 | 91 | 34 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 149 | 119 | 91 | 34 | 13 | Upgrade
|
| Shares Change (YoY) | 25.43% | 30.37% | 168.41% | 161.23% | 391.47% | Upgrade
|
| EPS (Basic) | -1.35 | -1.65 | -2.18 | -4.19 | -14.19 | Upgrade
|
| EPS (Diluted) | -1.35 | -1.65 | -2.18 | -4.19 | -14.19 | Upgrade
|
| Free Cash Flow | -167.1 | -130.16 | -174.14 | -147.92 | -38.23 | Upgrade
|
| Free Cash Flow Per Share | -1.12 | -1.10 | -1.91 | -4.37 | -2.95 | Upgrade
|
| Operating Margin | -4498.06% | -6787.36% | - | - | - | Upgrade
|
| Profit Margin | -4342.44% | -6566.61% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -3607.40% | -4363.36% | - | - | - | Upgrade
|
| EBITDA | -201.03 | -196.34 | -186.64 | -114.32 | -83.91 | Upgrade
|
| D&A For EBITDA | 7.32 | 6.13 | 4.65 | 2.22 | 0.57 | Upgrade
|
| EBIT | -208.35 | -202.47 | -191.29 | -116.54 | -84.47 | Upgrade
|
| Revenue as Reported | 4.63 | 2.98 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.